

Plasma Leptin Concentrations in Preterm Infants with Retinopathy of Prematurity (ROP)

Manizheh Mostafa Gharehbaghi¹, Ali Peirovifar², Karim Sadeghi³

Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Departments of pediatrics¹, anesthesiology², ophthalmology³

1- Associate professor of pediatrics and neonatology. Tabriz University of Medical Sciences (corresponding author)

2- Associate professor of Anesthesiology. Tabriz University of Medical Sciences

3 -Associate professor of ophthalmology. Tabriz University of Medical Sciences

Abstract

Introduction

Retinopathy of prematurity (ROP) is a postnatal disorder of retinal vessels that develops in the incompletely vascularized retina of preterm infants. This disorder regresses in most patients but can lead to severe visual impairment. There is evidence that leptin stimulates angiogenesis.

Objective: This study was conducted to determine blood levels of leptin in premature infants with proliferative ROP.

Methods:

Blood samples were obtained 6-8 weeks after birth from 71 preterm infants born at or before 32 weeks of gestation. These infants consisted of two groups according their eye examination results. The control group consisted of 41 neonates without evidence of ROP and the case group included 30 patients with proliferative ROP at stage III or more. Plasma leptin concentrations were measured using enzyme-linked immunosorbent assay (ELISA).

Results:

The mean gestation age of studied patients at birth were 28.4 ± 1.6 wk and 28.8 ± 1.6 in case and control group respectively ($P = .25$). The mean post menstrual age of studied patients at blood sampling was 34.9 ± 1.2 wk in the case group and 34.6 ± 1.3 wk in the control group ($p = 0.33$). Mean blood levels of leptin were not significantly different among patients of the two groups (0.64 ± 0.41 ng/ml in case group and 0.79 ± 0.83 ng/ml in control group respectively, $p = 0.39$).

Conclusion:

Our data demonstrated that plasma leptin concentrations were not significantly different in premature infants with proliferative ROP at 6-8 weeks after birth from premature infants without ROP at this age.

Key words:

Retinopathy of prematurity, Preterm infant, Leptin, Angiogenesis

Introduction

Despite recent advances in neonatal intensive care, the survival of preterm infants increased with no significant reduction in major morbidities such as retinopathy of prematurity (ROP), visual impairment and cognitive disabilities¹. ROP is a retinal vaso-proliferative disease associated with preterm birth. It is a major cause of blindness in children in the developed and developing countries. In addition to preterm birth and low birth weight, ROP associated with higher risk for

respiratory conditions, chronic respiratory disease, intra ventricular hemorrhage and blood transfusion².

Aberrant neo-vascularization is the hallmark of proliferative retinopathy as seen in ROP. Vascular endothelial growth factor (VEGF) is viewed as the major effector for ocular neovascularization^{3, 4}. Insulin like growth factor-1 (IGF-1) is main factor involved in the fetal tissue growth, including the retina. Premature birth results in a sudden fall in IGF-1 serum levels and development the first

stage of ROP5, 6. Beside these, other mediators such as erythropoietin, angiotensin II, endothelins

and leptin have been found to stimulate angiogenesis⁷.

Leptin, a 16 KDa protein of 167 amino acid, is an adipocyte derived hormone first discovered by Zhang et al in 1994⁸. Leptin regulates body weight and its serum levels reflect the amount of adipose tissue and positively correlate with the insulin resistance. Leptin is involved in a number of diverse physiologic processes, including endocrine functions, inflammation, immune responses and angiogenesis⁹⁻¹². It up regulates various pro-angiogenic factors such as CC-chemokine ligand 2, while it synergistically stimulates angiogenesis with vascular endothelial growth factor, indicating that leptin may contribute to the promotion of neo vascularization processes¹³. The exact role of leptin in retinal neo-vascularization is still not completely understood. This study aims to determine the relationship between serum leptin levels and the presence of proliferative ROP in preterm newborn infants.

Material and methods

All Preterm infants whose gestational age were 32 weeks of gestation or less and were examined for diagnosis of ROP in the neonatal intensive care unit (NICU) of Al-Zahra university teaching hospital, Tabriz, Iran from March 2009 to June 2010 were eligible for inclusion in this study. Newborn infants with chromosomal anomalies or major congenital malformations were excluded from the study. During the 18-month study period, 30 preterm newborn infants diagnosed with proliferative ROP were enrolled in the case group. Patients with ROP stage I or II were excluded from study. Forty-one infants with normal ophthalmologic examinations were randomly selected as controls. Gestational age was determined by either the maternal last menstrual period or first trimester ultrasound examination and confirmed by neonatal examination using Ballard gestational age scoring¹⁴. Each infant was examined initially when aged 4 weeks and repeated examinations were done at 2 week intervals if retinal vessels have grown only into zone II or every week in infants with vessels only as far as zone I. All eye examinations were performed by an ophthalmologist experienced in evaluating infants for ROP who had no knowledge of the study design. ROP was classified according to the international classification and subdivided

into stage I (demarcation line), stage II (ridge), stage III (ridge with external fibro vascular proliferation), stage IV (subtotal retinal

detachment) or stage V (total retinal detachment)¹⁵. Classification was done according to the most advance ROP stage observed. Proliferative ROP was defined as stage III or more. All infants with ROP stage III or more were enrolled in the case group. The ethic committee of Tabriz University of Medical Sciences approved the study and written informed parental consent was obtained in all cases.

Blood samples were collected at the time of follow up eye examination at 6-8 weeks of birth. The samples were centrifuged at 3000 rpm and stored at -70 degrees centigrade. The laboratory analysis was done by one blinded to the study.

Leptin concentrations were measured by quantitative sandwich enzymatic immunoassay technique (ELISA) by using leptin kits (Mediagnost, Germany) with a sensitivity of 0.2 ng/ml and inter-assay coefficients of 2.55%.

Statistical analyses were carried out using SPSS package version 15. Data were expressed as mean \pm SD and number (%). Continuous variables were compared using standard nonparametric statistics for paired and unpaired samples t-test. Frequency of data were compared using the chi-square test. P-values less than 0.05 were considered to be statistically significant.

Results

Seventy-one infants were included in this study, including 41 preterm neonates without ROP (control group) and 30 patients with proliferative ROP (case group). The mean gestation age (GA) and birth weight in case group was 28.2 ± 1.6 weeks and 1120.7 ± 197 gram and 28.4 ± 1.6 weeks 1189.4 ± 454 gram in control group $p=0.25$ and $p=0.44$ respectively. Some of demographic characteristics of studied patients are showed in Table 1.

Twelve patients in the case group (40%) and eight neonates in the control group (20%) were twins ($p=0.05$). Regarding respiratory management, there were not significant differences among patients of either group, except the need for surfactant replacement therapy. Surfactant replacement therapy was done for 11 (26.8%) patients in the control group and 15 (50%) of neonates in the case group ($P=0.04$). The mean duration of oxygen therapy was 30.8 ± 24.7 days in the case group and 25.8 ± 15.9 days in the control group ($p=0.31$). The mean serum leptin concentration in neonates who

had RDS was 0.64 ± 0.06 ng/ml which was not statistically different from neonates without RDS 0.77 ± 0.12 ng/ml ($p=0.44$). Although serum leptin levels were lower in neonates with

bronchopulmonary dysplasia than neonates without BPD (0.53 ± 0.03 vs. 0.83 ± 0.13 ng/ml) the difference was not statistically significant ($p=0.08$).

Table 1: Demographic characteristics of patients in two groups

	Case group N=30	Control group N=41	P-Value
Gestation age at birth, wk	28.4 ± 1.6 Range: 26-32	28.8 ± 1.6 Range: 26-34	0.25
Birth weight, g	$1120. \pm 196.$ Range: 780-1720	$1189. \pm 454.$ Range: 800-1750	0.44
Sex			0.25
male, n (%)	12 (40)	22 (53.7)	
PMA at sampling, wk	34.9 ± 1.2 Range: 33-37	34.6 ± 1.3 Range: 33-38	0.65
Apgar score			
1min	4.8 ± 1.4 Range: 2-7	6.5 ± 1.4 Range: 2-9	<0.001
5min	7.2 ± 1.4 Range: 3-9)	8.4 ± 1.3 Range: 6-10	0.001

Note: • mean \pm (SD)
PMA=post-menstrual age

The mean plasma levels of leptin in control group was 0.79 ± 0.83 ng/ml (range: 0.3- 5.2ng/ml) and in the case group was 0.64 ± 0.41 ng/ml (range: 0.2- 1.9 ng/ml) without significant difference ($p=0.39$). Diode laser photocoagulation was performed in 21 patients with proliferative ROP.

Discussion

Ischemia induced retinal neo-vascularization often results in loss of vision in the final stage of various ocular disease including diabetic retinopathy (DR), retinal vein occlusion, and ROP.

Studies in experimental animals have shown that leptin promotes neo-intimal growth in mice and stimulates migration of vascular smooth muscles 12, 16. Leptin may also activate adult human endothelial progenitor cells and promote angiogenesis 12.

Suganami and coworkers designed a study to elucidate the pathophysiological role of leptin in the progression of retinal neo-vascularization. They demonstrated more pronounced retinal neo-vascularization in 17 day-old transgenic mice over-expressing leptin. They concluded that leptin stimulates the ischemia induced retinal neo-vascularization possibly through the up regulation of VEGF 17.

There are observations suggest that leptin may played a role in the development of DR and its plasma concentrations are elevated significantly in patients with proliferative DR relative to those

with non-proliferative retinopathy 18. Vitreous leptin concentrations are higher in patients with proliferative DR or retinal detachment 19. However, whether leptin has as a causative role in DR or ROP is currently undefined. In our study plasma leptin concentrations was not significantly different among neonates with proliferative ROP and preterm infants without ROP. Interestingly, leptin concentrations were positively correlated with lung weight on the 7th day of life in lambs who received intravenous leptin that suggest its potential role in lung growth 20. While clinical studies based on mouse model observations, indicate the critical role of leptin on lung function in various conditions including asthma, heart failure, the pathophysiological significance of leptin regarding respiratory function in humans remains to be clarified 21. We did not find a significant difference among patients with RDS or BPD and infants without these respiratory problems with respect to serum leptin levels.

In our study lower Apgar score, multiple pregnancy and severe respiratory distress needing surfactant replacement therapy were significantly more common in patients who developed proliferative ROP. It is suggested there is need for strict control of oxygen use in neonatal resuscitation and after surfactant administration for management of respiratory distress syndrome.

A limitation of our study was the absence of serial measurements of leptin in different postnatal

ages; and we couldn't elucidate any variation of leptin over time.

In conclusion, our data demonstrated that plasma leptin concentrations were not significantly different in premature infants with proliferative ROP at 6-8 weeks after birth from premature infants without ROP at this age. Future studies with a larger number of neonates and at different post-natal ages to elucidate the role of leptin in pathogenesis of ROP are required.

Acknowledgments

The authors would like to thank the vice chancellor of research of the Tabriz University of Medical Sciences and the Women's Reproductive Health Research Center for providing funding for this study. We thank Dr. Zarghami, Dr. Mostafidi, Mr. Neginfar, Mrs. Atayan, and Mrs. Esmaeli for their help in sample collection and preparation. We also gratefully acknowledge the work done by the staff at neonatal intensive care unit and neonatal unit, Al Zahra Hospital, Tabriz, Iran.

References

- 1- Austeng D, Kallen KBM, Ewald UW, Jakobson PG, Helstrom GE. Incidence of retinopathy of prematurity in infants born before 27 week's gestation in Sweden. *Arch Ophthalmol* 2009; 127: 1315-1319.
- 2- Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the united states 1997 through 2005. *Am J Ophthalmol* 2009; 148: 451-458.
- 3- Aiello LP, Avery RL, Arrigg PG, Keyt BA, et al. vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 1994; 331: 1480-1487.
- 4- Villegas- Becerril E, Gonzalez-Fernandez R, Perula-Torres L, Gallardo-Galera JM. IGF-1, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity. *Arch Soc Esp Oftalmol* 2006; 81: 641-646.
- 5- Shaw LC, Grant MB. Insulin like growth factor -1 and insulin like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. *Rev Endocrine & Metabolic Dis* 2004; 5: 199-207.
- 6- Perez - Munuzuri A, Fernandez-Lorenzo JR, Couce-Pico ML, Blaneo-Teijeiro MJ, Fraga- Bermudez JM. Serum levels of IGF-1 are a useful predictor of retinopathy of prematurity. *Acta Paediatr* 2010; 99: 519-525.
- 7- Bisht M, Dhasmana DC, Bist SS. Angiogenesis: future of pharmacological modulation. *Indian J Pharmacol* 2010; 42 (1): 2-8.
- 8- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994; 372:425-432.
- 9- Loffredas S, Yang SQ, Lin HZ, Karp CL, Bergman ML, et al. leptin regulates pro-inflammatory immune responses. *FASEB J* 1998; 12: 57-65.
- 10- Maintgrete F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. *Diabetes* 2003; 52:2121-2128.
- 11- Momin AV, Melikian V, Shah AM, Grieve DJ, Whecraft SB, et al. Leptin is an endothelial independent vasodilator in human with coronary artery disease: evidence for tissue specificity of leptin resistance. *Eur Heart J* 2006; 27: 2294-2299.
- 12- Wolk R, Deb A, Caplice NM, Somers VK. Leptin receptor and functional effects of leptin in human endothelial progenitor cells. *Atherosclerosis* 2005; 183: 131-139.
- 13- Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Leptin enhances CC chemokine ligand expression in cultured murine macrophage. *Biochem Biophys Res Commun* 2009; 384(3): 311-315.
- 14- Ballard JL, Khory JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R (1991) New Ballard score, expanded to include extremely premature infants. *J Pediatr*; 119:417-423.
- 15- International committee for classification of retinopathy of prematurity the international classification of retinopathy of prematurity revisited. *Arch Ophthalmol* 2005; 123: 991-999.
- 16- Hassan-Ali H, El-Mottaleb NAA, Hamed HB, Abd-Elseyed A. Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. *Coronary Artery Dis* 2011; 22: 264-269.
- 17- Suganami E, Takagi H, Ohashi H, Suzuma K, et al. Leptin stimulates ischemia induced neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. *Diabetes* 2004; 53: 2443-2448.
- 18- Uckaya G, Ozata M, Bayraktar Z, Erten V, Bingol N, Ozdemir IC. Is leptin associated with diabetic retinopathy? *Diabetes Care* 2000; 23: 371-376.
- 19- Gariano RF, Nath AK, D'Amico DJ, Lee T, Sierra-Honigmann MR. Elevated vitreous leptin in diabetic retinopathy and retinal detachment. *Invest Ophthalmol Vis Sci* 2000; 41: 3576-3581.
- 20- Gnanalingham MG, Mostyn A, Fardner DS, Stephenson T, Symonds ME. Development regulation of the lung in preparation for life after birth: hormone and nutritional manipulation of local glucocorticoid action and uncoupling protein 2. *J Endocrinol* 2006; 188(3): 375-386.
- 21- Malli F, Papaionnou AI, Gourgoulisanis KI, Daniil Z. The role of leptin in the respiratory system: an overview. *Resp Res* 2010, 11: 152.

